tetano
Editor, Senior Moderator
Vaccine. 2015 May 30. pii: S0264-410X(15)00697-0. doi: 10.1016/j.vaccine.2015.05.045. [Epub ahead of print]
[h=1]A broad protection provided by matrix protein 2 (M2) of avian influenza virus.[/h] Meng Q[SUP]1[/SUP], Liu G[SUP]2[/SUP], Liu Y[SUP]3[/SUP], Deng X[SUP]4[/SUP], Wang W[SUP]3[/SUP], Xu K[SUP]4[/SUP], Zheng X[SUP]4[/SUP], Zhang D[SUP]4[/SUP], Pang H[SUP]5[/SUP], Chen H[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] To prevent a future influenza A virus subtype pandemic outbreak, developing a broad-spectrum vaccine would be highly beneficial. The ion channel protein M2 is highly conserved in a diverse number of influenza A virus subtypes. This distinguishing characteristic makes M2 an attractive vaccine target for a broadly protective vaccine. We expressed a full-length M2 protein which was C-terminally fused to a small peptide in Escherichia coli. Because this recombinant M2 (rM2) protein forms multimeric complexes with high molecular weight, it serves as a potential immunogen. Antibodies induced by the rM2 protein prevented the replication of different subtypes of influenza A virus both in vitro and in vivo. Animal study demonstrated that rM2 immunization protected mice against influenza A virus infection via limiting replication of virus progeny in vivo and attenuating lung damage. As such, the M2 protein is a highly potential candidate for next generation vaccine development with the capability of protecting against various influenza A virus subtypes.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Antibody; Influenza A virus; M2 protein; Protection; Vaccine
PMID: 26036948 [PubMed - as supplied by publisher]
[h=1]A broad protection provided by matrix protein 2 (M2) of avian influenza virus.[/h] Meng Q[SUP]1[/SUP], Liu G[SUP]2[/SUP], Liu Y[SUP]3[/SUP], Deng X[SUP]4[/SUP], Wang W[SUP]3[/SUP], Xu K[SUP]4[/SUP], Zheng X[SUP]4[/SUP], Zhang D[SUP]4[/SUP], Pang H[SUP]5[/SUP], Chen H[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] To prevent a future influenza A virus subtype pandemic outbreak, developing a broad-spectrum vaccine would be highly beneficial. The ion channel protein M2 is highly conserved in a diverse number of influenza A virus subtypes. This distinguishing characteristic makes M2 an attractive vaccine target for a broadly protective vaccine. We expressed a full-length M2 protein which was C-terminally fused to a small peptide in Escherichia coli. Because this recombinant M2 (rM2) protein forms multimeric complexes with high molecular weight, it serves as a potential immunogen. Antibodies induced by the rM2 protein prevented the replication of different subtypes of influenza A virus both in vitro and in vivo. Animal study demonstrated that rM2 immunization protected mice against influenza A virus infection via limiting replication of virus progeny in vivo and attenuating lung damage. As such, the M2 protein is a highly potential candidate for next generation vaccine development with the capability of protecting against various influenza A virus subtypes.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Antibody; Influenza A virus; M2 protein; Protection; Vaccine
PMID: 26036948 [PubMed - as supplied by publisher]